OTC Xyzal could lift Sanofi above EUR1bn in US

9 February 2017 - Deborah Wilkes

Archived

Launching an OTC version of the allergy medicine Xyzal (levocetirizine dihydrochloride) should lift Sanofi Consumer Healthcare's sales in the US above EUR1.0 billion (USD1.1 billion) in 2017, according to Alan Main, Sanofi's executive vice president Consumer Healthcare. In 2016, sales in the US reached EUR938 million.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: